Aristotle Atlantic’s Core Equity Strategy Sold Becton, Dickinson and Company (BDX) Due to Recent Earnings Weakness

2 hours ago 1

Soumya Eswaran

Mon, November 17, 2025 astatine 8:14 AM CST 3 min read

Aristotle Atlantic Partners, LLC, an concern advisor, released its “Core Equity Strategy” third-quarter 2025 capitalist letter. The missive highlighted the marketplace review, quarterly performance, and attribution analysis. A transcript of the missive tin beryllium downloaded here. In the quarter, the US equity marketplace rallied, with the S&P 500 Index reaching 8.12%. Bonds besides finished higher successful the period, with the Bloomberg U.S. Aggregate Bond Index expanding 2.03%. The composite has returned 7.22% gross of fees (7.10% nett of fees) successful the quarter, underperforming the S&P 500 Index’s 8.12% gain. Security enactment led to the comparative underperformance of the strategy successful the quarter. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Aristotle Atlantic Core Equity Strategy highlighted stocks specified arsenic Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX) is simply a healthcare institution that develops and manufactures aesculapian supplies, devices, laboratory equipment, and diagnostic products. The one-month instrumentality of Becton, Dickinson and Company (NYSE:BDX) was 1.07%, and its shares mislaid 13.86% of their worth implicit the past 52 weeks. On November 14, 2025, Becton, Dickinson and Company (NYSE:BDX) banal closed astatine $193.04 per share, with a marketplace capitalization of $55.33 billion.

Aristotle Atlantic Core Equity Strategy stated the pursuing regarding Becton, Dickinson and Company (NYSE:BDX) successful its 3rd 4th 2025 capitalist letter:

"We sold Becton, Dickinson and Company (NYSE:BDX) pursuing weakness related to its caller fiscal net quarter, wherever results showed interaction from cuts to definite programs funded by the National Institutes of Health (NIH). The institution chopped guardant net and gross guidance to bespeak weakness successful backing for biosciences probe and improvement (R&D) and the expected impacts of tariffs. While Becton is attempting to divest its Biosciences and Diagnostic Solutions divisions, we are not assured that it volition attain the champion worth fixed the cyclical downturn affecting these businesses. We judge it volition instrumentality clip for Becton to regain capitalist assurance and grow the company’s valuation."

Is Becton, Dickinson, and Company (BDX) the Best-Falling Stock to Buy According to Analysts?

Becton, Dickinson and Company (NYSE:BDX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge money portfolios held Becton, Dickinson and Company (NYSE:BDX) astatine the extremity of the 2nd quarter, up from 54 successful the erstwhile quarter. In the fiscal 4th fourth of 2025, Becton, Dickinson and Company’s (NYSE:BDX) gross grew 7% to $5.9 cardinal oregon 3.9% organic. While we admit the imaginable of Becton, Dickinson and Company (NYSE:BDX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.